Kymera Therapeutics, Inc. (NASDAQ:KYMR) Position Increased by Wellington Management Group LLP

Wellington Management Group LLP boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,307,326 shares of the company's stock after buying an additional 688,967 shares during the quarter. Wellington Management Group LLP owned 8.17% of Kymera Therapeutics worth $213,514,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock worth $196,617,000 after acquiring an additional 133,546 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after purchasing an additional 20,346 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Kymera Therapeutics by 14.1% in the 4th quarter. Schroder Investment Management Group now owns 163,896 shares of the company's stock valued at $6,444,000 after purchasing an additional 20,204 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock valued at $6,649,000 after buying an additional 95,547 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Kymera Therapeutics by 4.5% during the fourth quarter. Bank of New York Mellon Corp now owns 127,093 shares of the company's stock worth $5,113,000 after buying an additional 5,448 shares in the last quarter.

Remove Ads

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now owns 80,085 shares of the company's stock, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,659 shares of company stock worth $324,567. Company insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Down 0.3 %

KYMR stock traded down $0.06 during mid-day trading on Monday, reaching $22.01. The company had a trading volume of 1,181,078 shares, compared to its average volume of 534,735. Kymera Therapeutics, Inc. has a one year low of $19.75 and a one year high of $53.27. The stock has a market capitalization of $1.43 billion, a P/E ratio of -9.41 and a beta of 2.22. The stock's 50-day simple moving average is $33.63 and its two-hundred day simple moving average is $40.80.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KYMR shares. BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $60.00 price objective on the stock. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright boosted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Citigroup assumed coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Finally, Stephens reiterated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.